[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYrqou5ksaemzDgWNcxDiDeN-2lCoo8eHpBvuAkjd-IY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"Uppsala University Hospital",[4],70,false,17,0,610565,6,55,[14,17,19,21,24,26,28,30],{"name":15,"count":16},"Atrial Fibrillation",3,{"name":18,"count":16},"Eating Disorders",{"name":20,"count":16},"Anorexia Nervosa",{"name":22,"count":23},"Anesthesia",2,{"name":25,"count":23},"Cancer of Liver",{"name":27,"count":23},"Sepsis",{"name":29,"count":23},"Type 1 Diabetes",{"name":31,"count":23},"Mechanical Ventilation",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT04185831","A MolEcularly Guided Anti-Cancer Drug Off-Label Trial","2024-01-31","Atezolizumab",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04323566","Rituximab Treatment for Psychosis And\u002For Obsessive Compulsive Disorder with Probable Immune System Involvement","2028-04-01","Rituximab",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05061030","Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents","2028-09","the ATMP Protrans",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,80,110,135,153,171,189,225,252,270,288,314,340,365,391,417,447,465,483,501,519,537,561,587,605],{"intervention":47,"totalTrials":57,"cells":58},1,{"EARLY_PHASE1":59,"PHASE1":61,"PHASE2":63,"PHASE3":74,"PHASE4":76,"NA":78},{"trials":60,"activeCount":9},[],{"trials":62,"activeCount":9},[],{"trials":64,"activeCount":57,"soonestReadout":46},[65],{"nctId":44,"briefTitle":45,"status":66,"phases":67,"primaryCompletion":46,"completion":68,"start":69,"enrollment":70,"conditions":71,"interventions":73},"ACTIVE_NOT_RECRUITING",[50,51],"2028-12","2022-01-14",66,[72],"Type1diabetes",[47],{"trials":75,"activeCount":9},[],{"trials":77,"activeCount":9},[],{"trials":79,"activeCount":9},[],{"intervention":42,"totalTrials":57,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":83,"activeCount":9},[],{"trials":85,"activeCount":9},[],{"trials":87,"activeCount":57,"soonestReadout":41},[88],{"nctId":39,"briefTitle":40,"status":89,"phases":90,"primaryCompletion":41,"completion":91,"start":92,"enrollment":93,"conditions":94,"interventions":103},"ENROLLING_BY_INVITATION",[51],"2028-12-01","2022-05-01",40,[95,96,97,98,99,100,101,102],"Obsessive-Compulsive Disorder","Obsessive-Compulsive Behavior","Schizophrenia","Delusional Disorder","Brief Psychotic Disorder","Schizo Affective Disorder","Other Psychoses","Unspecified Psychosis",[42],{"trials":105,"activeCount":9},[],{"trials":107,"activeCount":9},[],{"trials":109,"activeCount":9},[],{"intervention":37,"totalTrials":57,"cells":111},{"EARLY_PHASE1":112,"PHASE1":114,"PHASE2":116,"PHASE3":129,"PHASE4":131,"NA":133},{"trials":113,"activeCount":9},[],{"trials":115,"activeCount":9},[],{"trials":117,"activeCount":57,"soonestReadout":36},[118],{"nctId":34,"briefTitle":35,"status":66,"phases":119,"primaryCompletion":36,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},[51],"2024-10","2020-10-20",167,[124],"Solid Tumor",[37,126,127,128],"Everolimus","Cobimetinib","Niraparib",{"trials":130,"activeCount":9},[],{"trials":132,"activeCount":9},[],{"trials":134,"activeCount":9},[],{"intervention":126,"totalTrials":57,"cells":136},{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":147,"PHASE4":149,"NA":151},{"trials":138,"activeCount":9},[],{"trials":140,"activeCount":9},[],{"trials":142,"activeCount":57,"soonestReadout":36},[143],{"nctId":34,"briefTitle":35,"status":66,"phases":144,"primaryCompletion":36,"completion":120,"start":121,"enrollment":122,"conditions":145,"interventions":146},[51],[124],[37,126,127,128],{"trials":148,"activeCount":9},[],{"trials":150,"activeCount":9},[],{"trials":152,"activeCount":9},[],{"intervention":127,"totalTrials":57,"cells":154},{"EARLY_PHASE1":155,"PHASE1":157,"PHASE2":159,"PHASE3":165,"PHASE4":167,"NA":169},{"trials":156,"activeCount":9},[],{"trials":158,"activeCount":9},[],{"trials":160,"activeCount":57,"soonestReadout":36},[161],{"nctId":34,"briefTitle":35,"status":66,"phases":162,"primaryCompletion":36,"completion":120,"start":121,"enrollment":122,"conditions":163,"interventions":164},[51],[124],[37,126,127,128],{"trials":166,"activeCount":9},[],{"trials":168,"activeCount":9},[],{"trials":170,"activeCount":9},[],{"intervention":128,"totalTrials":57,"cells":172},{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":183,"PHASE4":185,"NA":187},{"trials":174,"activeCount":9},[],{"trials":176,"activeCount":9},[],{"trials":178,"activeCount":57,"soonestReadout":36},[179],{"nctId":34,"briefTitle":35,"status":66,"phases":180,"primaryCompletion":36,"completion":120,"start":121,"enrollment":122,"conditions":181,"interventions":182},[51],[124],[37,126,127,128],{"trials":184,"activeCount":9},[],{"trials":186,"activeCount":9},[],{"trials":188,"activeCount":9},[],{"intervention":190,"totalTrials":23,"cells":191},"Dexmedetomidine",{"EARLY_PHASE1":192,"PHASE1":194,"PHASE2":196,"PHASE3":198,"PHASE4":200,"NA":223},{"trials":193,"activeCount":9},[],{"trials":195,"activeCount":9},[],{"trials":197,"activeCount":9},[],{"trials":199,"activeCount":9},[],{"trials":201,"activeCount":9},[202,213],{"nctId":203,"briefTitle":204,"status":205,"phases":206,"primaryCompletion":207,"completion":207,"start":208,"enrollment":209,"conditions":210,"interventions":212},"NCT02016391","Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours","COMPLETED",[53],"2014-12","2013-12",50,[211,25],"Cancer of Kidney and Renal Pelvis",[190],{"nctId":214,"briefTitle":215,"status":205,"phases":216,"primaryCompletion":217,"completion":217,"start":218,"enrollment":219,"conditions":220,"interventions":222},"NCT02044224","Effects of Dexmedetomidine During IRE Procedures for Solid Tumours",[53],"2015-09","2014-01",30,[25,221],"Cancer of Pancreas",[190],{"trials":224,"activeCount":9},[],{"intervention":226,"totalTrials":57,"cells":227},"Prednisolone + placebo",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":250},{"trials":229,"activeCount":9},[],{"trials":231,"activeCount":9},[],{"trials":233,"activeCount":9},[],{"trials":235,"activeCount":9},[],{"trials":237,"activeCount":9},[238],{"nctId":239,"briefTitle":240,"status":205,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT00510263","Scandinavian Bell's Palsy Study",[53],"2007-09","2001-05",839,[246],"Bell's Palsy",[226,248,249],"Valaciclovir + placebo","Prednisolone + valaciclovir",{"trials":251,"activeCount":9},[],{"intervention":248,"totalTrials":57,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":268},{"trials":255,"activeCount":9},[],{"trials":257,"activeCount":9},[],{"trials":259,"activeCount":9},[],{"trials":261,"activeCount":9},[],{"trials":263,"activeCount":9},[264],{"nctId":239,"briefTitle":240,"status":205,"phases":265,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":266,"interventions":267},[53],[246],[226,248,249],{"trials":269,"activeCount":9},[],{"intervention":249,"totalTrials":57,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":278,"PHASE4":280,"NA":286},{"trials":273,"activeCount":9},[],{"trials":275,"activeCount":9},[],{"trials":277,"activeCount":9},[],{"trials":279,"activeCount":9},[],{"trials":281,"activeCount":9},[282],{"nctId":239,"briefTitle":240,"status":205,"phases":283,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":284,"interventions":285},[53],[246],[226,248,249],{"trials":287,"activeCount":9},[],{"intervention":289,"totalTrials":57,"cells":290},"autologous mesenchymal stem cell transplantation",{"EARLY_PHASE1":291,"PHASE1":293,"PHASE2":295,"PHASE3":308,"PHASE4":310,"NA":312},{"trials":292,"activeCount":9},[],{"trials":294,"activeCount":9},[],{"trials":296,"activeCount":9},[297],{"nctId":298,"briefTitle":299,"status":300,"phases":301,"primaryCompletion":302,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":307},"NCT02057211","Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study","TERMINATED",[51],"2017-11","2014-04",10,[306],"Type 1 Diabetes Mellitus",[289],{"trials":309,"activeCount":9},[],{"trials":311,"activeCount":9},[],{"trials":313,"activeCount":9},[],{"intervention":315,"totalTrials":57,"cells":316},"Electrochemotherapy",{"EARLY_PHASE1":317,"PHASE1":319,"PHASE2":321,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":318,"activeCount":9},[],{"trials":320,"activeCount":9},[],{"trials":322,"activeCount":9},[323],{"nctId":324,"briefTitle":325,"status":326,"phases":327,"primaryCompletion":207,"completion":328,"start":329,"enrollment":9,"conditions":330,"interventions":333},"NCT01479946","Electrochemotherapy For The Treatment Of Breast Cancer That Has Spread to the Skin","WITHDRAWN",[51],"2015-06","2011-10",[331,332],"Breast Cancer","Skin Metastases",[315],{"trials":335,"activeCount":9},[],{"trials":337,"activeCount":9},[],{"trials":339,"activeCount":9},[],{"intervention":341,"totalTrials":57,"cells":342},"Acetazolamide",{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":359,"PHASE4":361,"NA":363},{"trials":344,"activeCount":9},[],{"trials":346,"activeCount":9},[],{"trials":348,"activeCount":9},[349],{"nctId":350,"briefTitle":351,"status":205,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":209,"conditions":356,"interventions":358},"NCT04975269","Acetazolamide Trial in Normal Pressure Hydrocephalus",[51],"2024-11-18","2026-04-21","2022-02-17",[357],"Idiopathic Normal Pressure Hydrocephalus (INPH)",[341],{"trials":360,"activeCount":9},[],{"trials":362,"activeCount":9},[],{"trials":364,"activeCount":9},[],{"intervention":366,"totalTrials":57,"cells":367},"Aprepitant",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":369,"activeCount":9},[],{"trials":371,"activeCount":9},[],{"trials":373,"activeCount":9},[374],{"nctId":375,"briefTitle":376,"status":205,"phases":377,"primaryCompletion":378,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":384},"NCT01101529","Treatment of Chemotherapy-induced Nausea and Vomiting",[51],"2012-12","2010-05",90,[382,383],"Nausea","Vomiting",[366],{"trials":386,"activeCount":9},[],{"trials":388,"activeCount":9},[],{"trials":390,"activeCount":9},[],{"intervention":392,"totalTrials":57,"cells":393},"Metformin",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":411,"PHASE4":413,"NA":415},{"trials":395,"activeCount":9},[],{"trials":397,"activeCount":9},[],{"trials":399,"activeCount":9},[400],{"nctId":401,"briefTitle":402,"status":403,"phases":404,"primaryCompletion":405,"completion":405,"start":406,"enrollment":407,"conditions":408,"interventions":410},"NCT04224051","Metformin for Abdominal Aortic Aneurysm Growth Inhibition","UNKNOWN",[51],"2026-01","2020-02-12",500,[409],"Abdominal Aortic Aneurysm",[392],{"trials":412,"activeCount":9},[],{"trials":414,"activeCount":9},[],{"trials":416,"activeCount":9},[],{"intervention":418,"totalTrials":57,"cells":419},"Amiodarone",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":430},{"trials":421,"activeCount":9},[],{"trials":423,"activeCount":9},[],{"trials":425,"activeCount":9},[],{"trials":427,"activeCount":9},[],{"trials":429,"activeCount":9},[],{"trials":431,"activeCount":9},[432],{"nctId":433,"briefTitle":434,"status":403,"phases":435,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":441},"NCT02294955","Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)",[54],"2018-09","2008-05",152,[15,440],"Quality of Life",[418,442,443,444,445,446],"Sotalol","Flecainide","Propafenone","Disopyramide","Dronedarone",{"intervention":442,"totalTrials":57,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":450,"activeCount":9},[],{"trials":452,"activeCount":9},[],{"trials":454,"activeCount":9},[],{"trials":456,"activeCount":9},[],{"trials":458,"activeCount":9},[],{"trials":460,"activeCount":9},[461],{"nctId":433,"briefTitle":434,"status":403,"phases":462,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":463,"interventions":464},[54],[15,440],[418,442,443,444,445,446],{"intervention":443,"totalTrials":57,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":468,"activeCount":9},[],{"trials":470,"activeCount":9},[],{"trials":472,"activeCount":9},[],{"trials":474,"activeCount":9},[],{"trials":476,"activeCount":9},[],{"trials":478,"activeCount":9},[479],{"nctId":433,"briefTitle":434,"status":403,"phases":480,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":481,"interventions":482},[54],[15,440],[418,442,443,444,445,446],{"intervention":444,"totalTrials":57,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":486,"activeCount":9},[],{"trials":488,"activeCount":9},[],{"trials":490,"activeCount":9},[],{"trials":492,"activeCount":9},[],{"trials":494,"activeCount":9},[],{"trials":496,"activeCount":9},[497],{"nctId":433,"briefTitle":434,"status":403,"phases":498,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":499,"interventions":500},[54],[15,440],[418,442,443,444,445,446],{"intervention":445,"totalTrials":57,"cells":502},{"EARLY_PHASE1":503,"PHASE1":505,"PHASE2":507,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":504,"activeCount":9},[],{"trials":506,"activeCount":9},[],{"trials":508,"activeCount":9},[],{"trials":510,"activeCount":9},[],{"trials":512,"activeCount":9},[],{"trials":514,"activeCount":9},[515],{"nctId":433,"briefTitle":434,"status":403,"phases":516,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":517,"interventions":518},[54],[15,440],[418,442,443,444,445,446],{"intervention":446,"totalTrials":57,"cells":520},{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":522,"activeCount":9},[],{"trials":524,"activeCount":9},[],{"trials":526,"activeCount":9},[],{"trials":528,"activeCount":9},[],{"trials":530,"activeCount":9},[],{"trials":532,"activeCount":9},[533],{"nctId":433,"briefTitle":434,"status":403,"phases":534,"primaryCompletion":436,"completion":436,"start":437,"enrollment":438,"conditions":535,"interventions":536},[54],[15,440],[418,442,443,444,445,446],{"intervention":538,"totalTrials":57,"cells":539},"Mesenchymal stem cells",{"EARLY_PHASE1":540,"PHASE1":542,"PHASE2":544,"PHASE3":546,"PHASE4":548,"NA":550},{"trials":541,"activeCount":9},[],{"trials":543,"activeCount":9},[],{"trials":545,"activeCount":9},[],{"trials":547,"activeCount":9},[],{"trials":549,"activeCount":9},[],{"trials":551,"activeCount":9},[552],{"nctId":553,"briefTitle":554,"status":205,"phases":555,"primaryCompletion":556,"completion":556,"start":557,"enrollment":558,"conditions":559,"interventions":560},"NCT01068951","Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells",[54],"2013-09","2010-06",20,[29],[538],{"intervention":562,"totalTrials":57,"cells":563},"Sucrosomial Iron",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":570,"PHASE4":572,"NA":574},{"trials":565,"activeCount":9},[],{"trials":567,"activeCount":9},[],{"trials":569,"activeCount":9},[],{"trials":571,"activeCount":9},[],{"trials":573,"activeCount":9},[],{"trials":575,"activeCount":9},[576],{"nctId":577,"briefTitle":578,"status":205,"phases":579,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":583,"interventions":585},"NCT05678647","Sucrosomial Iron and Iron Sulphate to Blood Donors",[54],"2026-03-01","2023-01-31",120,[584],"Blood Donation",[562,586],"Iron Sulfate",{"intervention":586,"totalTrials":57,"cells":588},{"EARLY_PHASE1":589,"PHASE1":591,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":590,"activeCount":9},[],{"trials":592,"activeCount":9},[],{"trials":594,"activeCount":9},[],{"trials":596,"activeCount":9},[],{"trials":598,"activeCount":9},[],{"trials":600,"activeCount":9},[601],{"nctId":577,"briefTitle":578,"status":205,"phases":602,"primaryCompletion":580,"completion":580,"start":581,"enrollment":582,"conditions":603,"interventions":604},[54],[584],[562,586],{"intervention":606,"totalTrials":57,"cells":607},"oxytocin",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":618},{"trials":609,"activeCount":9},[],{"trials":611,"activeCount":9},[],{"trials":613,"activeCount":9},[],{"trials":615,"activeCount":9},[],{"trials":617,"activeCount":9},[],{"trials":619,"activeCount":9},[620],{"nctId":621,"briefTitle":622,"status":205,"phases":623,"primaryCompletion":624,"completion":624,"start":625,"enrollment":626,"conditions":627,"interventions":629},"NCT01530230","ST- Depression on Electrocardiogram During Caesarean Section in Regional Anaesthesia in Women With Preeclampsia",[54],"2008-04","2005-11",25,[628],"Preeclampsia",[606]]